Srividya Swaminathan Lab
Research Lab Overview
A large number of lymphoid neoplasms are currently being treated with conventional chemotherapies that are toxic for normal cells. Of note, healthy lymphocytes express the normal counterparts of oncoproteins, making direct targeting of oncogenes difficult. Therefore, identification of therapies that can specifically target cancer cells is required. The immune system is a natural defense mechanism against cancers that can be activated to specifically kill malignant cells.
Development of targeted immunotherapy against lymphoid malignancies requires distinguishing normal and malignant lymphocytes in two respects: (1) Cell-intrinsic signaling, that includes surface molecules and intracellular signaling, and (2) Regulation of immune microenvironment. Srividya Swaminathan’s laboratory will study these aspects by comparing both cell-intrinsic processes, and the spatial and temporal distribution of the immune system during normal and malignant lymphopoiesis, using approaches including mass cytometry (CyTOF), CIBERSORT and humanized mouse models. This knowledge will be applied for the development of cell-based and other immunotherapies. Sponsors for the Swaminathan Lab research include the NCI/NIH, LLS, ASH, St. Baldrick's Foundation, Leukemia Research Foundation, Prevent Cancer Foundation, and Concern Foundation.
An Associate Professor in the Department of Systems Biology, Srividya Swaminathan's research focuses on immune profiling of normal and malignant lymphopoiesis, molecular mechanisms of immune modulation by oncogenes, development of cell-based and non-cell-based immunotherapies against lymphoid neoplasms.
Lab Members
Lab Alumni
Join one of our labs and help us on our mission to save lives.
Partnerships
We collaborate with organizations in progressing the development of new treatments in our specialized areas of research.
Contribute to our discoveries by donating.
Latest Research News
Contact Information
34.1293409, -117.971358
Duarte, CA 91010